INSUBCONTINENT EXCLUSIVE:
The WHO said licensed doses will only be available from the middle of next year
(File photo)Geneva: The World Health Organization (WHO) on Tuesday said it had prequalified an Ebola vaccine for the first time, hailing a
"critical step" towards its licensing, access and roll-out in countries most at risk of outbreaks."This is the fastest vaccine
prequalification process ever conducted by WHO," it said in a statement, explaining that "prequalification means that the vaccine meets WHO
standards for quality, safety and efficacy."The announcement comes hot on the heels of a decision last Monday by the European Commission to
allow the release to market of the injectable vaccine, Ervebo, made by US laboratory Merck Sharpe and Dohme (MSD) after the European
Medicines Agency gave the product its green light on October 18."This is a historic step towards ensuring the people who most need it are
able to access this life-saving vaccine," said WHO Director-General Tedros Adhanom Ghebreyesus."Five years ago, we had no vaccine and no
With a prequalified vaccine and experimental therapeutics, Ebola is now preventable and treatable," he added.WHO said Ervebo has been shown
to be effective in protecting people from the Ebola Zaire virus and added it is recommended by the organisation's Strategic Advisory Group
of Experts (SAGE) for vaccines as part of a broader set of Ebola response tools.The WHO said licensed doses will only be available from the
middle of next year.WHO said it had "accelerated prequalification by reviewing safety and efficacy data as the information became available"
and said it was engaged in facilitating licensing for use in countries at risk of Ebola outbreaks."WHO, with the support of EMA, has worked
closely with many African regulators who have indicated they will quickly license the vaccine following the WHO recommendation," the world
body said.Since the current epidemic, which has cost some 2,190 lives out of 3,290 declared cases since it began in DR Congo, more than
236,000 people have been treated, according to the WHO, including 60,000 health professionals, with the vaccine, known in the lab as
rVSV-ZEBOV-GP.Merck's vaccine was administered to them under an exceptional procedure, granting permission to use non-licensed drugs in
emergency cases.A second vaccine still at the experimental stage and developed by Johnson - Johnson for administration in two doses at
56-day intervals, is due to be introduced in the coming days in zones where the virus is as yet absent.The current epidemic in DR Congo is
the tenth in the country since the first in 1976
It is the second most deadly to date after a 2014-2016 outbreak which cost some 11,000 lives and underscored the urgency to bring a vaccine
to market.(Except for the headline, this story has not been edited by TheIndianSubcontinent staff and is published from a syndicated
feed.)Get Breaking news, live coverage, and Latest News from India and around the world on TheIndianSubcontinent.com
Catch all the Live TV action on TheIndianSubcontinent 24x7 and TheIndianSubcontinent India
Like us on Facebook or follow us on Twitter and Instagram for latest news and live news updates.
